JP2022500455A5 - - Google Patents
Info
- Publication number
- JP2022500455A5 JP2022500455A5 JP2021514418A JP2021514418A JP2022500455A5 JP 2022500455 A5 JP2022500455 A5 JP 2022500455A5 JP 2021514418 A JP2021514418 A JP 2021514418A JP 2021514418 A JP2021514418 A JP 2021514418A JP 2022500455 A5 JP2022500455 A5 JP 2022500455A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- antibody
- seq
- nlrp3
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1815045.8 | 2018-09-14 | ||
| GBGB1815045.8A GB201815045D0 (en) | 2018-09-14 | 2018-09-14 | Bispecific antibody targeting IL-1R1 and NLPR3 |
| PCT/EP2019/074744 WO2020053446A1 (en) | 2018-09-14 | 2019-09-16 | Bispecific antibody targeting il-1r1 and nlpr3 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500455A JP2022500455A (ja) | 2022-01-04 |
| JP2022500455A5 true JP2022500455A5 (enExample) | 2022-09-22 |
| JP7645544B2 JP7645544B2 (ja) | 2025-03-14 |
Family
ID=64013420
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514423A Active JP7517702B2 (ja) | 2018-09-14 | 2019-09-16 | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 |
| JP2021514418A Active JP7645544B2 (ja) | 2018-09-14 | 2019-09-16 | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 |
| JP2024104327A Pending JP2024125385A (ja) | 2018-09-14 | 2024-06-27 | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514423A Active JP7517702B2 (ja) | 2018-09-14 | 2019-09-16 | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024104327A Pending JP2024125385A (ja) | 2018-09-14 | 2024-06-27 | Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12264201B2 (enExample) |
| EP (2) | EP3849662A1 (enExample) |
| JP (3) | JP7517702B2 (enExample) |
| CN (2) | CN112996564A (enExample) |
| AU (2) | AU2019338955B2 (enExample) |
| GB (1) | GB201815045D0 (enExample) |
| WO (2) | WO2020053446A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| JP2024501033A (ja) * | 2020-12-28 | 2024-01-10 | エムディー ヘルスケア インコーポレイテッド | ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物 |
| US20250382341A1 (en) * | 2022-12-30 | 2025-12-18 | The Regents Of The University Of California | Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of |
| CN119925593B (zh) * | 2023-06-05 | 2025-11-25 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的药物制剂 |
| CN120535628B (zh) * | 2023-06-05 | 2025-11-25 | 北京东方百泰生物科技股份有限公司 | 一种抗il-11单克隆抗体的纯化方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1266004A2 (en) | 2000-02-17 | 2002-12-18 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
| AU2001296333A1 (en) | 2000-09-26 | 2002-04-08 | The Burnham Institute | Paad domain-containing polypeptides, encoding nucleic acids, and methods of use |
| WO2007077042A1 (en) | 2006-01-06 | 2007-07-12 | Topotarget Switzerland Sa | New method for the treatment of gout or pseudogout |
| US20080008652A1 (en) | 2006-01-10 | 2008-01-10 | The Regents Of The University Of Michigan | Methods and compositions for mediation of immune responses and adjuvant activity |
| FR2937339B1 (fr) | 2008-10-21 | 2013-02-15 | Univ Bourgogne | Procede de detection de la maladie atheromateuse. |
| US8298533B2 (en) | 2008-11-07 | 2012-10-30 | Medimmune Limited | Antibodies to IL-1R1 |
| WO2011109459A2 (en) | 2010-03-04 | 2011-09-09 | University Of Miami | Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases |
| CA2808185A1 (en) | 2010-08-13 | 2012-02-16 | Genentech, Inc. | Antibodies to il-1.beta. and il-18, for treatment of disease |
| US9707272B2 (en) * | 2011-07-12 | 2017-07-18 | Universitat Zurich | Method for the treatment of acne by administering IL-1β antibody |
| US10633451B2 (en) * | 2012-02-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine |
| EP2812697B1 (en) | 2012-02-06 | 2017-03-22 | University of Miami | Innate immune proteins as biomarkers for cns injury |
| EP2825561A4 (en) | 2012-03-15 | 2016-03-09 | Permeon Biolog Inc | CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE |
| AU2015204558B2 (en) * | 2014-01-10 | 2020-04-30 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
| US20160354437A1 (en) * | 2014-02-13 | 2016-12-08 | Northwestern University | Compositions and methods for modulation of immune response |
| CN104258398B (zh) * | 2014-10-14 | 2017-12-22 | 中国科学技术大学 | Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途 |
| US20170145412A1 (en) | 2015-11-04 | 2017-05-25 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting nlrp3 gene expression and uses thereof |
| JP2019069905A (ja) * | 2016-02-29 | 2019-05-09 | 国立大学法人大阪大学 | 組織損傷治療剤 |
| US20200115358A1 (en) * | 2016-03-11 | 2020-04-16 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Icariin and icaritin derivatives |
| WO2018022982A1 (en) * | 2016-07-29 | 2018-02-01 | Trustees Of Boston University | Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development |
-
2018
- 2018-09-14 GB GBGB1815045.8A patent/GB201815045D0/en not_active Ceased
-
2019
- 2019-09-16 WO PCT/EP2019/074744 patent/WO2020053446A1/en not_active Ceased
- 2019-09-16 US US17/275,986 patent/US12264201B2/en active Active
- 2019-09-16 EP EP19769487.0A patent/EP3849662A1/en active Pending
- 2019-09-16 CN CN201980074106.7A patent/CN112996564A/zh active Pending
- 2019-09-16 US US17/275,995 patent/US12227579B2/en active Active
- 2019-09-16 WO PCT/EP2019/074745 patent/WO2020053447A1/en not_active Ceased
- 2019-09-16 CN CN201980074059.6A patent/CN112996563A/zh active Pending
- 2019-09-16 JP JP2021514423A patent/JP7517702B2/ja active Active
- 2019-09-16 AU AU2019338955A patent/AU2019338955B2/en active Active
- 2019-09-16 EP EP19769486.2A patent/EP3849661A1/en active Pending
- 2019-09-16 JP JP2021514418A patent/JP7645544B2/ja active Active
- 2019-09-16 AU AU2019338674A patent/AU2019338674B2/en active Active
-
2024
- 2024-06-27 JP JP2024104327A patent/JP2024125385A/ja active Pending